Selenocompounds as Potent Efflux Pump Inhibitors on Gram‐positive Bacteria
Sign Up to like & getrecommendations! Published in 2024 at "Chemmedchem"
DOI: 10.1002/cmdc.202400691
Abstract: In recent years, selenocompounds have gained increasing attention as potential anticancer and antibacterial agents. Several selenoderivatives have been confirmed to act as MDR efflux pump inhibitors, based on their in vitro results against the bacterial AcrAB‐TolC… read more here.
Keywords: inhibitors gram; efflux pump; pump; selenocompounds potent ... See more keywords
Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1153
Abstract: Acalabrutinib is a Bruton tyrosine kinase (BTK) inhibitor approved to treat adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or previously treated mantle cell lymphoma. As the bioavailability of the acalabrutinib capsule (AC) depends on… read more here.
Keywords: proton pump; coadministration proton; bioavailability; pump inhibitors ... See more keywords
Association between proton pump inhibitors and periodontal disease severity.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical and experimental dental research"
DOI: 10.1002/cre2.495
Abstract: OBJECTIVES Proton pump inhibitors (PPIs) are commonly prescribed for the management of acid-related gastrointestinal disorders. PPIs modulate osteoclast function, reduce gastric acid secretion, and are associated with the establishment of a more diverse gastrointestinal microbiota.… read more here.
Keywords: proton pump; pump inhibitors; periodontal disease; probing depths ... See more keywords
The influence of proton pump inhibitors on tissue attachment around teeth and dental implants: A scoping review
Sign Up to like & getrecommendations! Published in 2022 at "Clinical and Experimental Dental Research"
DOI: 10.1002/cre2.616
Abstract: Proton pump inhibitors, such as omeprazole and pantoprazole, are frequently prescribed for the treatment of acid reflux. However, those medications have been shown to affect a variety of physiologic processes, including bone homeostasis and the… read more here.
Keywords: proton pump; teeth dental; around teeth; pump inhibitors ... See more keywords
Proton pump inhibitors, Enterococcus, and the liver, oh my!
Sign Up to like & getrecommendations! Published in 2018 at "Hepatology"
DOI: 10.1002/hep.29822
Abstract: humans. The need for a new model of HCV infection is acute. DAA therapy will likely have limited impact on HCV disease burden in the foreseeable future. Most HCV infections are undiagnosed and virus transmission… read more here.
Keywords: pump inhibitors; hcv; infection; enterococcus liver ... See more keywords
Letter to the Editor: Proton Pump Inhibitors Are Associated With Minimal and Overt Hepatic Encephalopathy and Increased Mortality in Patients With Cirrhosis
Sign Up to like & getrecommendations! Published in 2019 at "Hepatology"
DOI: 10.1002/hep.30641
Abstract: We read the paper by Nardelli et al with great interest.1 The study tried to establish the correlation between using of proton pump inhibitors (PPIs) and the occurrence of minimal/overt hepatic encephalopathy (HE) among cirrhotics. In… read more here.
Keywords: pump inhibitors; minimal overt; hepatic encephalopathy; proton pump ... See more keywords
Proton pump inhibitors: Review of reported risks and controversies
Sign Up to like & getrecommendations! Published in 2018 at "Laryngoscope Investigative Otolaryngology"
DOI: 10.1002/lio2.187
Abstract: Proton pump inhibitors (PPIs) are among the most prescribed classes of drugs in this day and age. These may be beneficial to treat many gastrointestinal conditions, such as gastroesophageal reflux or Barrett's esophagus as well… read more here.
Keywords: pump inhibitors; reported risks; review reported; inhibitors review ... See more keywords
Long‐term use of proton pump inhibitors and prevalence of disease‐ and drug‐related reasons for gastroprotection—a cross‐sectional population‐based study
Sign Up to like & getrecommendations! Published in 2017 at "Pharmacoepidemiology and Drug Safety"
DOI: 10.1002/pds.4135
Abstract: To analyse the prevalence of long‐term use of proton pump inhibitors (PPI) with respect to underlying diseases and drugs, and to find predictors for such treatment when an evident rationale for the PPI treatment is… read more here.
Keywords: pump inhibitors; long term; use proton; proton pump ... See more keywords
Proton pump inhibitors and chronic kidney disease: Reevaluating the evidence from a randomized controlled trial
Sign Up to like & getrecommendations! Published in 2020 at "Pharmacoepidemiology and Drug Safety"
DOI: 10.1002/pds.5101
Abstract: Proton pump inhibitors (PPIs) are among the most widely prescribed medications worldwide. However, these products are often overprescribed and used for unwarranted long durations, contributing to substantial expense, polypharmacy, and potential adverse reactions. Evidence from… read more here.
Keywords: pump inhibitors; kidney; chronic kidney; proton pump ... See more keywords
Proton pump inhibitors may enhance the risk of citalopram‐ and escitalopram‐associated sudden cardiac death among patients receiving hemodialysis
Sign Up to like & getrecommendations! Published in 2022 at "Pharmacoepidemiology and Drug Safety"
DOI: 10.1002/pds.5428
Abstract: Polypharmacy is common in the hemodialysis population and increases the likelihood that patients will be exposed to clinically significant drug–drug interactions. Concurrent use of proton pump inhibitors (PPIs) with citalopram or escitalopram may potentiate the… read more here.
Keywords: proton pump; citalopram escitalopram; hemodialysis; pump inhibitors ... See more keywords
Assessing Impact of Concomitant Use of Proton Pump Inhibitors and Clopidogrel on Incidence of Major Adverse Cardiovascular Events: A Retrospective Cohort Study
Sign Up to like & getrecommendations! Published in 2025 at "Pharmacoepidemiology and Drug Safety"
DOI: 10.1002/pds.70226
Abstract: Clopidogrel, an antiplatelet agent used to prevent ischemic events, may interact with proton pump inhibitors (PPIs), especially omeprazole and esomeprazole, and reduce its effectiveness. The evidence surrounding this interaction remains controversial. This study investigates whether… read more here.
Keywords: adverse cardiovascular; proton pump; major adverse; incidence major ... See more keywords